Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium Tc 99m SY101
- Development stage
- Phase 1
- Lead developer
- Shanghai Shiya Pharmaceutical Technology
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
SY101 is a prostate-specific membrane antigen (PSMA)-targeting small-molecule radioligand labeled with Technetium-99m ([99mTc]), developed by Shanghai Shiya Pharmaceutical Technology in collaboration with MITRO Biotech. It is designed as a diagnostic radiopharmaceutical for the detection and imaging of PSMA-positive prostate cancer. By binding specifically to the extracellular domain of PSMA, which is highly overexpressed in prostate cancer cells, the drug allows for high-contrast Single Photon Emission Computed Tomography (SPECT) imaging. This enables clinicians to evaluate disease extent, select patients for PSMA-targeted therapies, and monitor treatment response. The compound is currently undergoing clinical evaluation to assess its safety, pharmacokinetics, biodistribution, and radiation dosimetry.
- Other names
- Technetium-99m SY101Technetium99m SY101Technetium 99m SY101[99mTc]SY101
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on technetium Tc 99m SY101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium Tc 99m SY101.